The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Non-alcoholic Steatohepatitis Market Research Report 2024

Global Non-alcoholic Steatohepatitis Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1794559

No of Pages : 86

Ask Your Query

Synopsis

Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.

The global Non-alcoholic Steatohepatitis market was valued at US$ 2532 million in 2023 and is anticipated to reach US$ 9500.6 million by 2030, witnessing a CAGR of 20.6% during the forecast period 2024-2030.

NASH is a progressive liver disease characterized by fat accumulation in the liver, inflammation, and liver cell damage, typically occurring in individuals who do not consume excessive alcohol. Several factors are driving the growth of the NASH market. Firstly, the rising prevalence of obesity and metabolic disorders, such as diabetes and dyslipidemia, is contributing to the increasing incidence of NASH. Unhealthy lifestyles, sedentary habits, and poor dietary choices are leading to a higher risk of developing NASH, creating a substantial patient population in need of diagnosis and treatment. Secondly, the improved understanding and awareness of NASH among healthcare professionals and the general population have resulted in increased diagnosis rates. As the medical community recognizes the long-term complications and progression of NASH, there is a greater emphasis on identifying patients with NASH and implementing appropriate management strategies.

This report aims to provide a comprehensive presentation of the global market for Non-alcoholic Steatohepatitis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-alcoholic Steatohepatitis.

Report Scope

The Non-alcoholic Steatohepatitis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-alcoholic Steatohepatitis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-alcoholic Steatohepatitis companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • AstraZeneca
  • Pfizer
  • GSK
  • Novo Nordisk
  • Roche
  • AbbVie
  • Galectin Therapeutics
  • Galmed Pharmaceuticals
  • Gilead
  • Intercept pharma
  • Non-alcoholic Steatohepatitis
  • Takeda

Segment by Type

  • Solid
  • Liquid

Segment by Application

  • Oral
  • Parenteral

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-alcoholic Steatohepatitis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-alcoholic Steatohepatitis Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Solid
1.2.3 Liquid
1.3 Market by Application
1.3.1 Global Non-alcoholic Steatohepatitis Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oral
1.3.3 Parenteral
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-alcoholic Steatohepatitis Market Perspective (2019-2030)
2.2 Non-alcoholic Steatohepatitis Growth Trends by Region
2.2.1 Global Non-alcoholic Steatohepatitis Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-alcoholic Steatohepatitis Historic Market Size by Region (2019-2024)
2.2.3 Non-alcoholic Steatohepatitis Forecasted Market Size by Region (2025-2030)
2.3 Non-alcoholic Steatohepatitis Market Dynamics
2.3.1 Non-alcoholic Steatohepatitis Industry Trends
2.3.2 Non-alcoholic Steatohepatitis Market Drivers
2.3.3 Non-alcoholic Steatohepatitis Market Challenges
2.3.4 Non-alcoholic Steatohepatitis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-alcoholic Steatohepatitis Players by Revenue
3.1.1 Global Top Non-alcoholic Steatohepatitis Players by Revenue (2019-2024)
3.1.2 Global Non-alcoholic Steatohepatitis Revenue Market Share by Players (2019-2024)
3.2 Global Non-alcoholic Steatohepatitis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-alcoholic Steatohepatitis Revenue
3.4 Global Non-alcoholic Steatohepatitis Market Concentration Ratio
3.4.1 Global Non-alcoholic Steatohepatitis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-alcoholic Steatohepatitis Revenue in 2023
3.5 Non-alcoholic Steatohepatitis Key Players Head office and Area Served
3.6 Key Players Non-alcoholic Steatohepatitis Product Solution and Service
3.7 Date of Enter into Non-alcoholic Steatohepatitis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-alcoholic Steatohepatitis Breakdown Data by Type
4.1 Global Non-alcoholic Steatohepatitis Historic Market Size by Type (2019-2024)
4.2 Global Non-alcoholic Steatohepatitis Forecasted Market Size by Type (2025-2030)
5 Non-alcoholic Steatohepatitis Breakdown Data by Application
5.1 Global Non-alcoholic Steatohepatitis Historic Market Size by Application (2019-2024)
5.2 Global Non-alcoholic Steatohepatitis Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-alcoholic Steatohepatitis Market Size (2019-2030)
6.2 North America Non-alcoholic Steatohepatitis Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-alcoholic Steatohepatitis Market Size by Country (2019-2024)
6.4 North America Non-alcoholic Steatohepatitis Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-alcoholic Steatohepatitis Market Size (2019-2030)
7.2 Europe Non-alcoholic Steatohepatitis Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-alcoholic Steatohepatitis Market Size by Country (2019-2024)
7.4 Europe Non-alcoholic Steatohepatitis Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-alcoholic Steatohepatitis Market Size (2019-2030)
8.2 Asia-Pacific Non-alcoholic Steatohepatitis Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-alcoholic Steatohepatitis Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-alcoholic Steatohepatitis Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-alcoholic Steatohepatitis Market Size (2019-2030)
9.2 Latin America Non-alcoholic Steatohepatitis Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-alcoholic Steatohepatitis Market Size by Country (2019-2024)
9.4 Latin America Non-alcoholic Steatohepatitis Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-alcoholic Steatohepatitis Market Size (2019-2030)
10.2 Middle East & Africa Non-alcoholic Steatohepatitis Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-alcoholic Steatohepatitis Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-alcoholic Steatohepatitis Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Non-alcoholic Steatohepatitis Introduction
11.1.4 AstraZeneca Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Non-alcoholic Steatohepatitis Introduction
11.2.4 Pfizer Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Non-alcoholic Steatohepatitis Introduction
11.3.4 GSK Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.3.5 GSK Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Detail
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Introduction
11.4.4 Novo Nordisk Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.4.5 Novo Nordisk Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Non-alcoholic Steatohepatitis Introduction
11.5.4 Roche Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.5.5 Roche Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Non-alcoholic Steatohepatitis Introduction
11.6.4 AbbVie Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.6.5 AbbVie Recent Development
11.7 Galectin Therapeutics
11.7.1 Galectin Therapeutics Company Detail
11.7.2 Galectin Therapeutics Business Overview
11.7.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Introduction
11.7.4 Galectin Therapeutics Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.7.5 Galectin Therapeutics Recent Development
11.8 Galmed Pharmaceuticals
11.8.1 Galmed Pharmaceuticals Company Detail
11.8.2 Galmed Pharmaceuticals Business Overview
11.8.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Introduction
11.8.4 Galmed Pharmaceuticals Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.8.5 Galmed Pharmaceuticals Recent Development
11.9 Gilead
11.9.1 Gilead Company Detail
11.9.2 Gilead Business Overview
11.9.3 Gilead Non-alcoholic Steatohepatitis Introduction
11.9.4 Gilead Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.9.5 Gilead Recent Development
11.10 Intercept pharma
11.10.1 Intercept pharma Company Detail
11.10.2 Intercept pharma Business Overview
11.10.3 Intercept pharma Non-alcoholic Steatohepatitis Introduction
11.10.4 Intercept pharma Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.10.5 Intercept pharma Recent Development
11.11 Non-alcoholic Steatohepatitis
11.11.1 Non-alcoholic Steatohepatitis Company Detail
11.11.2 Non-alcoholic Steatohepatitis Business Overview
11.11.3 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Introduction
11.11.4 Non-alcoholic Steatohepatitis Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.11.5 Non-alcoholic Steatohepatitis Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Non-alcoholic Steatohepatitis Introduction
11.12.4 Takeda Revenue in Non-alcoholic Steatohepatitis Business (2019-2024)
11.12.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock